Sunshine Lake Pharma (HKG:6887) obtained marketing approval for the Olorigliflozin Capsules from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The approval is for use of the drug as monotherapy or in combination with metformin to improve glycemic control in adults with type 2 diabetes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.